Trial Profile
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Sep 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Measles mumps and rubella virus vaccine; Pneumococcal 10-valent vaccine conjugate; Pneumococcal vaccine conjugate
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi Pasteur
- 27 Jun 2023 Status changed from active, no longer recruiting to completed.
- 28 May 2023 This trial has been completed in Poland.
- 17 May 2023 This trial has been completed in Finland, according to European Clinical Trials Database record.